
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions speaks about the possible change of the pathway program due to alternative payment models, such as the Oncology Care Model.
Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions speaks about the possible change of the pathway program due to alternative payment models, such as the Oncology Care Model. The movement may be either a top-down, payer-sponsored initative or a bottom-up development at a practice level.






